Spinal Cord Stimulation for Persistent Spinal Pain Syndrome Type II: A Systematic Review and Subgroup Meta-analysis of Randomized Controlled Trials

This systematic review and meta-analysis of nine randomized controlled trials indicates that spinal cord stimulation provides clinically meaningful pain relief for Persistent Spinal Pain Syndrome type II patients, with high-frequency stimulation demonstrating superior efficacy for back pain and burst stimulation showing advantages in reducing continuous pain intensity, though significant heterogeneity and a lack of head-to-head comparisons currently preclude definitive treatment guidelines.

The Gist

Imagine you've had back surgery, but instead of feeling better, the pain is still there, or it's even worse. This frustrating condition is called Persistent Spinal Pain Syndrome Type II (PSPS-T2), or what used to be known as "Failed Back Surgery Syndrome." It's like fixing a flat tire on a car, only to find out the engine is still making a terrible noise.

For decades, doctors have tried to fix this with a device called Spinal Cord Stimulation (SCS). Think of this device as a "pacemaker for your nerves." It sends tiny electrical signals to your spinal cord to trick your brain into thinking the pain isn't there.

This paper is a massive review of the best scientific studies (Randomized Controlled Trials) to answer one big question: Which type of electrical signal works best?

Here is the breakdown of their findings, explained simply:

1. The "One Size Does Not Fit All" Discovery

The researchers found that the "best" type of stimulation depends entirely on where your pain is located. It's like trying to fix a leaky roof; you need a different tool for a hole in the shingles than you do for a crack in the foundation.

• For Leg Pain (The "Old Reliable"):
  If your pain shoots down your legs (radicular pain), the old-school method works just fine. This is called Tonic Stimulation. It's like a steady, low-frequency hum.

  • The Result: About 55% of people get significant relief. It's a solid, proven solution that doesn't need fancy new tech.

• For Back Pain (The "Game Changer"):
  If your pain is stuck right in the lower back (axial pain), the old-school "hum" often fails. It's like trying to put out a forest fire with a water pistol.

  • The New Heroes: The study found that High-Frequency and Burst stimulation are the superheroes here.
    • High-Frequency (10 kHz): Imagine a super-fast, silent vibration that you can't even feel. It's like a high-speed laser cutting through the pain. 92% of people got major relief with this!
    • Burst Stimulation: This is like a rhythmic drumbeat (short bursts of energy) rather than a constant hum. It also worked much better than the old method for back pain.

2. The "Paresthesia" Problem (The Tingle Factor)

The old method (Tonic) works by creating a "tingling" sensation (paresthesia) that covers up the pain. Imagine trying to cover a loud noise with a slightly louder noise.

• The Problem: To cover back pain, you have to turn the tingle up so high it becomes uncomfortable, like a mosquito buzzing right next to your ear.
• The Solution: The new High-Frequency and Burst methods are "Paresthesia-Free." They work silently, like a noise-canceling headphone that blocks out the pain without you feeling the "tingle." This makes them much more comfortable for back pain.

3. The "Who Wins?" Summary

• Leg Pain: Stick with the classic, low-cost Tonic stimulation. It works well and is cheaper.
• Back Pain: Switch to the fancy High-Frequency or Burst stimulation. It's significantly more effective, but it might cost more and require a rechargeable battery (since it uses more power).

4. The "Catch" (Things to Keep in Mind)

The authors are honest about the limitations of their study:

• The "Hype" Factor: Many of the studies were funded by the companies that make the devices. It's like a car company testing its own car; they might be a little too enthusiastic about the results. The real-world benefit might be slightly lower than the numbers suggest.
• The "Blind" Problem: It's very hard to do a "blind" study (where the patient doesn't know which treatment they are getting) because the new methods feel different (or don't feel anything) compared to the old ones. This makes it hard to know if the improvement is the device or just the patient's hope.
• Side Effects: Like any surgery, there are risks. About 16% of people needed a second surgery to fix or replace the device. Infections and hardware failures happen, but they are relatively rare (around 5-10%).

The Bottom Line

If you have leg pain, the old, reliable method is still your best bet. But if you have back pain, the new "silent" technologies (High-Frequency or Burst) are a massive leap forward, offering relief to almost everyone who tries them.

The Future: The paper suggests that in the future, doctors won't just pick one "best" device for everyone. Instead, they will act like tailors, measuring your specific pain (back vs. leg) and customizing the electrical "recipe" just for you.

Note: This paper is a preprint, meaning it hasn't been officially peer-reviewed by other scientists yet, so doctors should treat these findings as very promising but still in the "final draft" stage.

Technical Summary

1. Problem Statement

Persistent Spinal Pain Syndrome Type II (PSPS-T2), formerly known as Failed Back Surgery Syndrome (FBSS), affects 10–40% of patients following lumbar spine surgery. It presents a significant clinical challenge characterized by persistent or recurrent pain despite anatomically successful procedures.

• Therapeutic Gap: While traditional low-frequency tonic SCS (40–60 Hz) has established efficacy for radicular (leg) pain (~50–60% responder rates), it demonstrates inconsistent and often poor efficacy for axial (back) pain.
• Limitations of Existing Evidence: Previous meta-analyses relied heavily on mean pain score changes, which can mask bimodal response patterns (where some patients achieve substantial relief while others do not) and fail to provide actionable data for individual patient selection. Furthermore, high statistical heterogeneity ($I^2 > 75\%$) in prior studies has obscured the comparative effectiveness of newer waveforms (burst and high-frequency) versus conventional tonic stimulation.

2. Methodology

The study adhered to PRISMA 2020 guidelines and was registered with PROSPERO (CRD420251138521).

• Data Sources: A comprehensive search of PubMed/MEDLINE, Embase, and Scopus was conducted from inception through May 2025, with an update on October 3, 2025.
• Inclusion Criteria:
  • Design: Randomized Controlled Trials (RCTs) only.
  • Population: Adults with PSPS-T2 (post-surgical back/leg pain).
  • Interventions: Any SCS modality (tonic, burst, high-frequency, etc.) compared against other modalities, sham, or conventional management.
  • Outcomes: Must report pain intensity (VAS) or functional disability (ODI) at 6 or 12 months, specifically including responder rates ($\ge$50% pain reduction).
• Exclusion Criteria: Mixed etiologies where PSPS-T2 could not be isolated, trial-only data without permanent implantation, crossover studies (due to analysis constraints), and non-RCTs.
• Statistical Analysis:
  • Primary Outcome: Pooled proportion of patients achieving $\ge$50% pain reduction (responder analysis) using DerSimonian-Laird random-effects models.
  • Secondary Outcomes: Mean VAS and ODI scores at 6 and 12 months.
  • Subgroup Analyses: Stratified by stimulation type (Tonic vs. Burst) and frequency (High-frequency $\ge$1 kHz vs. Low-frequency <1 kHz).
  • Heterogeneity & Bias: Assessed via $I^2$, Cochran's Q, and meta-regression. Risk of bias was evaluated using the Cochrane RoB 2.0 tool. Publication bias was assessed via funnel plots, Egger's test, and trim-and-fill analysis.

3. Key Contributions

• Responder-Based Analysis: Shifted the focus from mean score changes to the proportion of patients achieving clinically meaningful relief ($\ge$50% reduction), aligning with IMMPACT recommendations for substantial improvement.
• Phenotype-Specific Efficacy: Provided granular data distinguishing between axial (back) and radicular (leg) pain responses across different waveforms.
• Meta-Regression: Identified specific patient-level predictors (age, pain duration, baseline severity) that influence treatment success, offering insights into patient selection algorithms.
• Critical Appraisal of Bias: Explicitly highlighted the "sponsorship effect," noting that 8 of 9 included RCTs were industry-sponsored, which may inflate efficacy estimates compared to investigator-initiated trials.

4. Key Results

Study Characteristics:

• Included: 9 RCTs with 565 patients.
• Risk of Bias: Only 2 studies (Rigoard et al. 2020; De Andres et al. 2017) demonstrated a low risk of bias across all domains. Most studies had high risk, primarily due to lack of blinding (D2) and unblinded outcome measurement (D4).

Efficacy Outcomes:

• Overall Responder Rates:
  • Back Pain: 45% (95% CI: 18–75%, $I^2=92.2\%$).
  • Leg Pain: 55% (95% CI: 45–65%, $I^2=0\%$).
• Modality Comparison (Back Pain):
  • High-Frequency (HF) SCS: Demonstrated significantly superior responder rates compared to conventional low-frequency (LF) stimulation (92% vs. 28%, $p < 0.001$).
  • Burst vs. Tonic: Burst stimulation showed significantly lower continuous VAS scores for back pain at 3 and 12 months compared to tonic stimulation.
• Modality Comparison (Leg Pain):
  • No significant difference in responder rates between modalities. Tonic (51%) and Burst (60%) performed similarly ($p=0.36$).
• Continuous Pain Scores (VAS):
  • Back Pain: Baseline 73.03 $\to$ 35.66 at 12 months.
  • Leg Pain: Baseline 61.81 $\to$ 29.16 at 12 months.
  • HF vs. LF (Leg Pain): At 6 months, HF SCS yielded significantly lower VAS scores (13.30) compared to LF (28.42, $p < 0.0001$).
• Functional Outcomes (ODI):
  • Baseline 51.75 $\to$ 30.07 at 12 months.
  • HF SCS showed significantly lower ODI scores at 6 months (22.92) compared to LF (36.15, $p=0.001$).

Predictors of Response (Meta-Regression):

• Positive Predictors: Longer pain duration and older age were associated with higher responder rates.
• Negative Predictor: Higher baseline leg pain scores predicted lower responder rates.

Safety and Tolerability:

• Serious Adverse Events (SAEs): 10%.
• Revision Surgery: 16% (high heterogeneity, $I^2=71\%$).
• Infection: 6%.
• Satisfaction: 91% of patients reported satisfaction.

Publication Bias:

• Trim-and-fill analysis suggested that industry sponsorship and small-study effects may have led to an overestimation of efficacy, particularly for newer waveforms. The single independent trial (De Andres et al.) reported more conservative results.

5. Significance and Clinical Implications

• Paradigm Shift for Back Pain: The study provides robust evidence that High-Frequency (10 kHz) SCS is superior to conventional tonic stimulation for axial back pain in PSPS-T2, achieving a 92% responder rate. This addresses the historical "axial gap" where traditional SCS failed.
• Leg Pain Stability: For radicular leg pain, traditional tonic SCS remains a validated, cost-effective standard, as newer waveforms (burst/HF) do not offer statistically significant superiority in responder rates, though HF may offer faster or greater pain intensity reduction.
• Personalized Medicine: The findings support a phenotype-driven approach:
  • Axial-dominant pain: Prioritize High-Frequency or Burst SCS.
  • Radicular-dominant pain: Tonic SCS remains a viable first-line neuromodulation option.
• Future Directions: The authors call for large-scale, head-to-head RCTs with standardized protocols and independent funding to validate these findings and reduce bias. They also suggest future algorithms should incorporate machine learning to predict individual waveform responses based on pain phenotype and patient history.

Conclusion: While High-Frequency and Burst SCS represent a significant advancement for managing refractory back pain in PSPS-T2, the choice of waveform should be dictated by the pain phenotype (axial vs. radicular) and patient-specific factors, rather than a "one-size-fits-all" approach.